SAGE Therapeutics Inc. (SAGE)

169.30
NASDAQ : Health Technology
Prev Close 169.11
Day Low/High 167.72 / 173.75
52 Wk Low/High 79.88 / 193.56
Avg Volume 355.80K
Exchange NASDAQ
Shares Outstanding 51.65M
Market Cap 8.74B
EPS -8.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Here’s Why Sage Therapeutics (SAGE) Stock is Tumbling Today

Here’s Why Sage Therapeutics (SAGE) Stock is Tumbling Today

Sage Therapeutics (SAGE) stock is plunging on Wednesday after Kerrisdale Capital said it had shorted the stock and that its experimental drug would likely fail an important late stage study.

Tesla, Amazon and Netflix: Doug Kass' Views

Tesla, Amazon and Netflix: Doug Kass' Views

Doug Kass shares his views on why technicals bode ill for tech.

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass

Doug Kass looks at Carl Icahn's actions on Apple and the breakout in biotech stocks.

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

Doug Kass shares his views on the health of the banking sector and why he's buying biotech.

General Motors, MetLife and Tesla: Doug Kass' Views

General Motors, MetLife and Tesla: Doug Kass' Views

Doug Kass shares his views on why he's staying short of GM and MetLife despite steep declines in both stocks.

Sage Therapeutics Stock Sees Short Interest Jump 12%

Sage Therapeutics Stock Sees Short Interest Jump 12%

The most recent short interest data has been released by the NASDAQ for the 01/29/2016 settlement date, which shows a 288,977 share increase in total short interest for Sage Therapeutics Inc , to 2,679,665, an increase of 12.09% since 01/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?

Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?

Biotech news and observations to start the week.

SAGE Updates Guidance For Top-Line Results Of Phase 3 STATUS Trial Of SAGE-547

SAGE Updates Guidance For Top-Line Results Of Phase 3 STATUS Trial Of SAGE-547

Top-Line Data Expected in Second Half of 2016 for SAGE's Global Phase 3 Trial in Super-Refractory Status Epilepticus

SAGE To Present Three Poster Presentations At The American Epilepsy Society 69th Annual Meeting

SAGE To Present Three Poster Presentations At The American Epilepsy Society 69th Annual Meeting

Sage Therapeutics (NASDAQ: SAGE) today announced upcoming medical/scientific poster presentations at the American Epilepsy Society 69 th Annual Meeting, taking place from December 4-8, 2015 at the Pennsylvania...

SAGE Announces Initiation Of Phase 1 And First Dosing Of SAGE-217

SAGE Announces Initiation Of Phase 1 And First Dosing Of SAGE-217

SAGE's First Oral Compound From Its Pipeline of Next Generation CNS Modulators Enters Clinical Development

SAGE Therapeutics Expands Leadership Team With Key Appointments

SAGE Therapeutics Expands Leadership Team With Key Appointments

Strategic Additions Broaden Organizational Capabilities as SAGE Advances Novel Therapeutics in Clinical and Late-Stage Development

Sage Psychiatric Drug Shows Activity Hint in Small Muscle Tremor Study

Sage Psychiatric Drug Shows Activity Hint in Small Muscle Tremor Study

The signal of activity Sage Therapeutics sees with SAGE-547 in essential tremor may turn out to be real or a mirage.

SAGE Announces First Patient Treated In Phase 3 STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus

SAGE Announces First Patient Treated In Phase 3 STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus

STATUS Trial of SAGE-547 is First Global Phase 3 Trial of Patients With SRSE, a Rare and Life-Threatening Seizure Disorder With no Approved Therapies

SAGE Receives Special Protocol Assessment For Phase 3 STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus

SAGE Receives Special Protocol Assessment For Phase 3 STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus

Provides FDA Agreement on Trial Design, Endpoints and Statistical Approach of the Phase 3 STATUS Trial

TheStreet Quant Rating: D (Sell)